SEC Company Response from Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Jul 26, 2016

Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: July 26, 2016 · CIK: 0001671502 · Accession: 0001144204-16-114558

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-212432

Date

July 26, 2016

Author

H.C. WAINWRIGHT & CO., LLC

Form

CORRESP

Company

Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)

Letter

Re: CELLECT BIOTECHNOLOGY LTD.

July 26, 2016

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form F-1 (Registration No. 333-212432) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering, hereby concurs in the request by Cellect Biotechnology Ltd. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on July 28, 2016, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text

CORRESP
1
filename1.htm

July 26, 2016

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 Re: CELLECT BIOTECHNOLOGY LTD.

  Registration Statement on Form F-1 (Registration No. 333-212432) -

  Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright &
Co., LLC (“Wainwright”), as representative of the underwriters for the referenced offering, hereby concurs in
the request by Cellect Biotechnology Ltd. that the effective date of the above-referenced registration statement be accelerated
to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on July 28, 2016, pursuant to Rule 461 under the Securities
Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.

    Very truly yours,

    H.C. WAINWRIGHT & CO., LLC

    By:
    /s/ Mark W. Viklund

    Name: Mark W. Viklund

    Title: Chief Executive Officer

SecProbe.io